Venom Peptides Lasioglossin II and Mastoparan B as Escherichia coli ATP synthase Inhibitors by Bello, Rafiat Ajoke
East Tennessee State University
Digital Commons @ East
Tennessee State University
Electronic Theses and Dissertations Student Works
8-2016
Venom Peptides Lasioglossin II and Mastoparan B
as Escherichia coli ATP synthase Inhibitors
Rafiat Ajoke Bello
East Tennessee State University
Follow this and additional works at: https://dc.etsu.edu/etd
Part of the Integrative Biology Commons
This Thesis - Open Access is brought to you for free and open access by the Student Works at Digital Commons @ East Tennessee State University. It
has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Digital Commons @ East Tennessee State
University. For more information, please contact digilib@etsu.edu.
Recommended Citation
Bello, Rafiat Ajoke, "Venom Peptides Lasioglossin II and Mastoparan B as Escherichia coli ATP synthase Inhibitors" (2016). Electronic
Theses and Dissertations. Paper 3112. https://dc.etsu.edu/etd/3112
Venom Peptides Lasioglossin II and Mastoparan B as  
Escherichia coli ATP synthase Inhibitors 
 
 
A thesis  
presented to the  
Department of Biological Sciences  
East Tennessee State University 
 
 
In partial fulfillment of  
the requirements for the degree 
 Master of Science in Biology 
 
 
by  
Rafiat Bello  
August 2016 
 
 
 
Thomas F. Laughlin, PhD, Chair  
Thomas C. Jones, PhD  
Dhirendra Kumar, PhD  
Bert C. Lampson, PhD 
 
Keywords: Antimicrobial Peptides, Venom Peptides, Lasioglossin II, Mastoparan B, F1FO ATP 
Synthase, ATPase Activity 
 
  
 
2 
 
ABSTRACT 
Venom Peptides Lasioglossin II and Mastoparan B as  
Escherichia coli ATP synthase Inhibitors 
by 
Rafiat Bello 
 
The inhibitory effects on Escherichia coli ATPase activity by two venom peptides, lasioglossin 
II and mastoparan B. Membrane bound F1FO ATP synthase was isolated from E. coli strain 
pBWU13.4/DK8 and treated with varied concentrations of lasioglossin II and mastoparan B. 
Lasioglossin II caused very low inhibition of ATPase activity, but the inhibition profile of 
mastoparan B was suggestive of an interesting biological effect. A relatively shorter total length, 
a smaller net positive charge, and a reduced amphipathic character of both peptides, as compared 
to previously tested antimicrobial peptides, may account for the limited degree of inhibition 
observed in the present study. 
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CHAPTER 1 
INTRODUCTION 
Several natural and synthetic compounds have been described as inhibitors of ATP 
synthase. One such group of inhibitors are Antimicrobial Peptides (AMPs). Several possible 
mechanisms have been described regarding the activity of AMPs. The most accepted models are 
membrane permeabilization and cell death (apoptosis) by either toroidal pore model, barrel stave 
model, or carpet model. Mechanism of activity studies suggest that AMPs seem to connect with 
negatively charged, anionic phospholipid layers thereby injecting itself into the bacterial cell 
membrane. AMPs can also extend over the cell membrane by passive transport upsetting some of 
the cellular activities in there. Dermaseptins seem to induce a non-pore dependent cytolytic 
process that results in breakdown and miscellization of the membrane bilayer (Shai 2002). A 
previously examined hypothesis concerning the antimicrobial effects of AMPs is based on their 
possible inhibitory effects on ATP synthase. This hypothesis was motivated by the observation 
that several other peptides which conform to basic amphiphilic α-helical structures are reported 
to bind at the βDELSEED-loop of E. coli ATP synthase (Ahmad et al. 2015). 
Ahmad and Laughlin (2010) discussed the concept that amphibian AMPs with possible 
inhibitory effects on ATP synthase, through binding at the βDELSEED-loop, would be relatively 
short positively charged peptides of ~10-30 amino acid residues, with α-helical secondary 
structure, and has antibacterial or anticancer effects. Previous studies suggested that in a state of 
low adenosine-5‘-triphosphate (ATP) and high H+ gradients concentrations, the C-terminal α-
helical domain of the ε-subunit of F1-ATPase experience enormous structural changes then join 
with the α3β3 hexagon ring, where it is places in the vicinity of the βDELSEED-loop (Ahmad et 
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al. 2015). Electrostatic interactions between basic residues of the ε-subunit and the acidic 
residues of βDELSEED-motif result in inhibition of ATPase activity (Hara et al. 2001b; Tsunoda 
et al. 2001; Suzuki et al. 2003). Inhibition of ATP synthase has been demonstrated to defend or 
delay cell damage by conserving ATP during ischaemia (Vuorinen et al. 1995). Because short 
linear cationic α-helical peptides with antimicrobial activity would be fascinating candidates as 
therapeutic agents, I examined the venom peptides mastoparan B and lasioglossin II as possible 
inhibitors of Escherichia coli ATP synthase. 
 
Hypothesis 
Venom peptides Mastoparan B and lasioglossin II can inhibit Escherichia coli ATP 
synthase activity. 
 
ATP synthase is a ubiquitous multi-subunit membrane enzyme that participate and plays 
a major role in cellular energy production. This membrane bound enzyme is found in almost 
every living cell. ATP synthase is highly conserved and structurally homologous in all 
organisms. In prokaryotes, ATP synthase is embedded in the plasma membrane, but it is located 
in the thylakoid membrane of chloroplasts of higher plants, and in the inner membrane of 
mitochondria in eukaryotic cells. ATP synthase is also spot on the exterior of various 
mammalian cell kinds, including endothelial cells, adipocytes, and keratinocytes (Hong and 
Pedersen 2008). ATP synthase is the terminal enzyme in the oxidative phosphorylation pathway. 
It activates ATP synthesis by oxidative phosphorylation or by photophosphorylation in the 
membranes of cells and organelles (Ahmad and Laughlin 2010). ATP synthase utilizes energy 
from a proton motive force generated by the electron transport chain to catalyze the production 
  
 
10 
 
of adenosine-5‘-triphosphate (ATP) from adenosine-5‘-diphosphate (ADP) and inorganic 
phosphate (Pi). In some bacteria, ATP synthase reverses this activity by functioning as an ATP-
driven proton pump that generates a proton (H+) gradient. The energy available from ATP is 
used for a number of cellular processes, including active transport of molecules across cell 
membranes, transport of nutrients, motility, nucleic acid synthesis, and protein synthesis. 
 
Inhibitors of ATP Synthase 
The inhibitory eﬀects on ATP synthase, and the range of inhibition are fluctuating on a 
molar scale among various inhibitors. Inhibitors can be classified based on bond formation 
(Gledhill and Walker 2006) and other physical and chemical properties (Hong and Pedersen 
2008). 
Based on bond formation with ATP synthase, they are grouped into two types. 
1. The covalent inhibitors include 4-chloro-7-nitrobenzofurazan (NBD-Cl), N,N΄-
dicyclohexylcarbodiimide (DCCD), 8-azido-ATP, 2-azido-ATP, 5΄-p-fluorosulphonyl-
benzoyladenosine and 5΄-p-fluorosulphonylbenzoylinosine.   
2. The non-covalent inhibitors include natural inhibitor protein IF1, amphiphilic peptides, 
non-peptidyl lipophilic cations, polyphenolic phytochemicals, non-hydrolysable substrate 
analogues, aurovertins and efrapeptins. 
Based on other physical and chemical properties of inhibitors, they are grouped into nine 
types. 
1. Peptide inhibitors include: 
• α-Helical basic peptide inhibitors: include the natural inhibitor protein IF1, 
bacterial/chloroplast ε subunit, antimicrobial peptides (AMP) like melittin, 
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dermaseptin, maculatin, aurein and venom peptides such as mastoparan B and 
lasioglossin II 
• Angiostatin and enterostatin 
• Leucinostatins and efrapeptins 
• Tentoxin and its derivatives 
Efrapeptin is an effective strong inhibitor of soluble ATP synthase compared to other 
compounds known to inhibit this enzyme like aurovertin and citreoviridin, efrapeptin is capable 
of causing maximium inhibition (Jackson et al. 1979). The binding site for the F1 targeting 
inhibitor efrapeptin is found in α, β and γ subunits (Abrahams et al. 1996) while that of 
aurovertin B is primarily confined to the β subunit (van Raajj et al. 1996).  
2. Polyphenolic phytochemicals, estrogens and structurally related compounds include:  
• Flavones and isoflavones: including quercetin, kaempfero, thymoquinone, morin 
apigenin, genistein, biochanin A and daidzein.  
• Stilbenes: including resveratrol, piceatannol, diethylstilbestrol (DES), 
diisothiocyanatostilbene- 2,2-disulfonic acid (DIDS) and 4-acetamido-4-
isothiocyanostilbene 2,2 -disulfonate (SITS).  
• Steroidal estradiols and estrogen metabolites: including 4-hydroxyestradiol, 2-
hydroxyestradiol, 17-α-estradiol, 17-β-estradiol α-zearalenol and β-zearalenol. 
• Other polyphenolic phytochemicals: including epicatechin gallate (ECG), 
epigallocatechin gallate (EGCG), curcumin, phloretin, theaflavin and tannic acid. 
Oestradiol and several other oestrogens have been shown to inhibit the activity of rat brain 
FOF1-ATPase (Zheng and Ramirez, 1999). A synthetic oestrogen, diethylstilbestrol has also been 
reported to inhibit rat liver FOF1-ATPase (McEnery and Pedersen 1986; McEnery et al. 1989). 
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Flavones like quercetin, which are weak oestrogenic phytochemicals, have been reported to 
inhibit bovine and porcine heart FOF1-ATPase (Lang and Racker 1974; Di Pietro et al. 1975). 
Thymoquinone, a major phytochemical compound found in the black seeds of the medicinal 
plant Nigella sativa, was shown to strongly inhibit ATPase activity and bacterial growth (Ahmad 
et al. 2015). Piceatannol inhibits ATP synthase by targeting the F1 sector and exhibits mixed 
inhibition of F1-ATPase activity (Zheng and Ramirez 1999). Resveratrol was found to show a 
non-competitive inhibition of F1-ATP synthase activity (Zheng and Ramirez 2000). 
3. Polyketide inhibitors that are polymers of two carbon ketide units synthesized by the 
enzyme polyketide synthases. These types include natural macrolides like apoptolidin, 
cytovaricin, oligomycin, peliomycin, ossamycin, and venturicidin. 
Oligomycin is the inhibitor that led to the name 'FO’ for the intramembrane hydrophobic 
region of ATP synthase. Oligomycin inhibits the apoptosis incited by Bax, a pro-apoptotic Bcl-2 
family member protein found on the mitochondrial outer membrane, and ATP synthase activity 
is needed for the killing of cells by Bax (Matsuyama et al. 1998). Oligomycin also activate 
apoptosis in tumour cells (Wolvetang et al. 1994).  
4. Organotin compounds and structural relatives: These are tin containing organic 
compounds. They are grouped into R4Sn, R3SnX, R2SnX2, and RSnX3. Examples 
include; tributyltin chloride, tricyclohexyltin hydroxide, triethyltin sulfate, triphenyltin 
chloride and triethyllead, etc (Von Ballmoos et al. 2004). 
5. Polyenic α-pyrone derivatives: α-Pyrone (a six membered cyclic unsaturated ester) and 
its derivatives are known to inhibit ATP synthase. Derivatives include aurovertin, 
citreoviridin and asteltoxin (Hong and Pedersen 2008). 
6. Cationic inhibitors: 
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• Amphiphilic cationic dyes containing a basic amine group and a lipophilic 
portion. They include rhodamine 123, acridine orange, rhodamine 6G, rosaniline, 
rhodamine B, malachite green, quinacrine, pyronin Y, safranin O, nile blue A and 
ethidium bromide (EtBr). 
• Tertiary amine local anesthetics (TALAs) which consist of an aromatic group, an 
middle chain, and a terminal amine group. They include tetracaine, dibucaine, 
procaine, lidocaine, chlorpromazine, trifluoperazine, trifluoperazine and 
propranolol. 
• Other organic cations such as octyl guanidine, spermidine, atrazine, PDT-ferrous 
chelate and DPBP-ferrous chelate (Hong and Pedersen 2008). 
7. Substrates and substrate analogs that include phosphate analogs, divalent metal ions, 
purine nucleotides and nucleotide analogs. 
8. Amino acid modifiers that include amino group modifiers, carboxyl group modifiers, 
cysteine and tyrosine residue modifiers and histidine residue modifiers  
9. Miscellaneous inhibitors that include dicarbopolyborate, almitrine, n-butanol, 4,4΄-
dichlorodiphenyltrichloroethane (DDT) and 4,4΄-dichlorodiphenyltri- chloroethane 
(DMSO) (Hong and Pedersen 2008). 
 
Antimicrobial Peptides 
Antimicrobial peptides are a unique and diverse group of active biological molecules that 
are produced by different organisms as a valuable and crucial constituent of their innate immune 
system. Most AMPs have similar features such as cationicity and amphipathicity. They are 
generally comprised of 12 to 50 amino acids, but differ in several characteristics including their 
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primary structure, the presence of disulphide bonds, and in a number of posttranslational changes 
like amidation of C-terminal residues, pyroglutamation of N-terminal glutamine residues, 
sulphation of tyrosine, hydroxylation of proline, and racemisation of certain L-amino acids to 
their D-isomers (Bevins and Zasloff 1990; Erspamer 1994). Based on their secondary structure 
AMPs follow four structural themes: α-helical peptides, β-stranded peptides, extended peptides 
and β-hairpin or loop peptides (Dhople et al. 2006). Previous studies have demonstrated that they 
often have wide spectrum activity against viruses, fungi, bacteria, protozoans, parasites and 
cancerous cells.  
The basic function of AMPs is host protection by making use of cytotoxicity to 
pathogenic organisms. AMPs bind to negatively charged residues of microbial membranes where 
peptide complexes form pores that break down the cell membrane or disturb metabolic processes 
in the target. They also play immune modulators in more advanced organisms (Zanetti 2004).  In 
addition to their antimicrobial function, AMPs may be used as antitumor agents, contraceptive 
agents, mitogenic agents, drug delivery vectors, and signaling molecules in signal transduction 
pathways (Kamysz et al. 2003). Laughlin and Ahmad 2010 report the first candid experimental 
proof of amphibian antimicrobial peptides as potential E. coli ATP synthase inhibitors testing 
samples from both purified F1 - ATPase and membrane bound F1FO - ATP synthase. Currently, 
there are more than 2700 entries into the Antimicrobial Peptide Database (APD) 
(http://aps.unmc.edu/AP/main.php Wang et al. 2015), out of which 2255 (83.14%) are known to 
have antibacterial property, 988 (36.43%) have antifungal property, 196 (7.22%) are anticancer 
peptides, and 177 (6.52%) are identified as having antiviral activity. The diversity of 
antimicrobial peptides apparently reflects adaptation to the particular microbial communities 
associated with the environments of different species (Boman 2000). 
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Linear cationic α-helical Peptides; Mastoparans and Lasioglossins 
Linear cationic α-helical peptides are small peptides rich in hydrophobic and basic amino 
acid residues. They are usually 10 to 45 amino acid residues long.  They can adopt α-helical 
amphipathic secondary structure in the cell membrane environment, or in the presence of such 
membrane, and thereby have effects similar to substances such as trifluoroethanol (TFE) or 
sodium dodecyl sulfate (SDS). They are often found in insects, and amphibian skin, as well as 
arthropod venoms, and possess antimicrobial activity against a wide range of bacteria (Cerovsky 
et al. 2008). Venoms are a highly evolved and rich source of natural cocktails of biochemically 
active enzymes, proteins, peptides and other molecules, each of which plays a defined role 
through interaction with highly specific molecular targets. Venom peptides have very strong and 
selective effects, and may serve as potential drugs or scaffolds for drug design. Many venom 
peptides are used in proof-of-concept studies in vivo, with many undergoing preclinical or 
clinical development for use in the treatment of diabetes, epilepsy, multiple sclerosis, 
cardiovascular disorders, pain, cancer and other neurological disorders. Captopril (Capoten; 
Anakena) from the Brazilian arrowhead viper (Bothrops jaracusa), was the first model of a 
successful venom-based drug. This drug inhibits angiotensin converting enzyme (ACE), a vital 
enzyme in the production of angiotensin, which is in turn a vasoconstrictor affiliated with 
hypertension (Cushmann and Ondetti 1991). Chlorotoxin, a peptide derived from the venom of 
the desert scorpion Leiurus quinquestriatus, has been established as an effective treatment for 
malignant glioma (Soroceanu et al. 1998). Exenatide, a synthetic analogue of exendin-4, the 
venom peptide of the gila monster lizard Heloderma suspectum, is ready for use as a prescription 
medicine in the treatment of Type 2 diabetes and related metabolic disorder (Nielsen et al. 2004).  
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Mastoparans are the mast cell degranulating peptides from the venoms of vespid wasps 
(Vespidae), has been identified as the dominant peptide found in the venoms of several species 
of hornets (Nakajima 1984). They are tetradecapeptides characterized by 7 - 10 hydrophobic 
amino acid residues and from 2 - 4 lysine residues in their basic sequence (Nakajima 1986). 
Mastoparans also form the most abundant class of peptides in the venoms of social wasps (Hirai 
et al. 1979). Their biological characteristics include the activation of enzymes like phospholipase 
A2, phospholipase C, guanylate cyclase and G proteins (Higashijima et al. 1990; Dong-Li et al. 
1993). Mastoparan is an effective stimulator of exocytosis in many mammalian cell types. 
Mastoparan causes the secretion of histamine from mastocytes, catecholamines from 
pheochromocytes, serotonin from thrombocytes, and prolactin from the adenohypophysis (Hirai 
et al. 1979; Kuroda et al. 1980; Kurihara et al. 1986). When mastoparan interact with the 
phospholipid bilayer it creates an α-helical structure that aligned to the surface of the membrane, 
the hydrophobic region is inside the bilayer with its four positive charges (three Lys residues and 
a terminal amino group) lining the exterior (Higashijima 1983; Wakamatsu et al. 1983).  
Mastoparan B from the venom of the hornet species Vespa basalis has high mast cell 
degranulation activity, a mastocytotropic peptide, with well-defined amino-acid sequence 
different from the other vespid mastoparans. Explicit differences in amino acid sequence were 
present at positions 1, 2, 5, 8 and 9, where mastoparan B has less hydrophobic amino acids like 
Leul, Lys2, Ser5,8 and Trp9, rather than Ile1, Asn2, Ala5,8 and Leu9 or other amino acids as seen in 
many other Vespa mastoparans (Hirai et al. 1979). When compared to the sequence of the 
prototypic mastoparan (Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2) 
(Hirai et al. 1979), mastoparan B may present a more hydrophilic surface, potentially causing 
differences in its biological activity. 
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Lasioglossins are members of a distinct group of AMPs that are found in the venom of 
the wild eusocial bee Lasioglossum laticeps. These peptides exhibit strong antimicrobial activity, 
low haemolytic activity, and cytotoxic activity against various cancer cells in vitro (Cerovsky et 
al. 2008). Lasioglossins has a net charge of +6 fitting within the broad class of essential AMPs 
with net charge varying from +4 to +6, which symbolize the maximum charge for antimicrobial 
activity (Tossi et al. 2000). They exhibit low mast cell degranulation activity. The VNWK 
sequence structure of lasioglossins is similar to the INWK sequence structure of a few 
mastoparans obtained from other species of social wasps (Čeřovský et al. 2008). 
 
Vespa basalis Mastoparan B sequence 
H-Leu-Lys-Leu-Lys-Ser-Ile-Val-Ser-Trp-Ala-Lys-Lys-Val-Leu-NH2 
 
Lasioglossum laticeps Lasioglossin II (LL-II) sequence 
H-Val-Asn-Trp-Lys-Lys-Ile-Leu-Gly-Lys-Ile-Ile-Lys-Val-Ala-Lys-NH2 
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Figure 1. Helix-wheel plots of venom peptides sequence mastoparan B and lasioglossin II (LL-
II). The size of the downward arrow ↓ reflects the extent of hydrophobicity. Hydrophobic and 
hydrophilic faces are shown in yellow and blue colors respectively. (http://heliquest.ipmc.cnrs.fr/ 
Gautier et al. 2008). 
 
Potential Mechanism of Action of Antimicrobial Peptide 
Antimicrobial peptides are thought to be structured such that they interact with a 
biomembrane. The initial mechanism by which AMPs target pathogens occurs by means of an 
electrostatic synergy between positive charged antimicrobial peptides and the negatively charged 
lipid membranes of bacteria. In receptor-mediated membrane interactions, some antimicrobial 
peptides expressly bind to bacterial lipid II, a negatively charged membrane bound constituent 
tangled in peptidoglycan synthesis (Yeaman and Yount 2003). 
After initial membrane binding, AMPs may go into a second phase of membrane 
connection known as the threshold concentration. Peptides infiltrate and crisscross the lipid 
Mastoparan B  Lasioglossin II (LL-II)  
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bilayer by mean of several probable methods, amplifying their antimicrobial activity to focus on 
the inner cell membrane. Theoretically, the threshold concentration needed to propel such 
occurrence is caused by a build-up of peptides on the cell membrane. A number of factors 
including tendency to self-associate or multimerization, peptide concentration, fluidity, 
phospholipid membrane constitution, and head group size likely influence this threshold (Yang 
et al. 2000). After membrane binding, another major event happening is the peptide structural or 
conformational phase transformation. The peptides immediately adopt a well-structured 
amphipathic α-helical conformation in membrane mimetic solvents, or upon interaction with 
phospholipid bilayers. β-sheet antimicrobial peptides are consistently organized in membrane 
environments and aqueous solution, because of constraints dictated by cyclization of the peptide 
backbone or disulfide bonds. Self-assemble or multimerize of antimicrobial peptides may occur 
following initial binding with the target cell membranes. Peptide-lipid and peptide-peptide 
interactions inside membranes apparently form elaborate structures affiliated with individual 
antimicrobial peptide mode of action (Yeaman and Yount 2003). 
  Membrane permeation by amphipathic α-helical or β-sheet peptides is thought to proceed 
via one of the following mechanisms: 
1. In the Barrel Stave Mechanism, the ‘stave’ caption alludes to individual transmembrane 
rods within this barrel, which consist of single peptides or peptide complexes. Here, 
varying amount of channel building peptides are placed in a barrel like loop about the 
aqueous pores. The hydrophobic planes of α-helical or β-sheet peptide faces outside 
towards the acyl chains of the membrane, while the hydrophilic planes make the pore 
lining (Breukink and Kruijff 1999). 
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2. In the Toroid Pore or Wormhole Mechanism, peptides in the outer cellular environment 
assume the α-helical form as they correspond with the negatively charged hydrophobic 
bacterial membrane. Lipids are inserted with peptides in the transmembrane channel, 
forming a structure known as the supramolecular complex, which epitomize a membrane-
spanning pore lined with the polar surfaces of peptides and the phospholipid head groups. 
The hydrophobic residues of the connected peptides dislocate the polar head groups, 
generating a gap in the hydrophobic plane and activating positive curvature strain in the 
cell membrane (Hara et al. 2001a). The commencement of strain and thinning appears to 
further destabilize the membranes surface quality making it also liable to change with 
subsequent peptide connections. Some peptide may become displaced to the cytoplasmic 
leaflet of the membrane upon fragmentation of the pore. Uematsu and Matsuzaki (2000) 
suggest that toroid pore break down might be the major mechanism through which 
peptides move into the microbial cytoplasm to affect possible intracellular destinations. 
3. The Carpet Mechanism model, some peptides oppose microorganisms in a comparably 
diffuse mode. This is a model of nonspecific membrane permeabilization by AMPs 
which includes widespread results that have been compared to detergents. However, 
peptides in this mechanism are not indiscriminate membrane detergents. Here, a high 
mass of peptide aggregates on the target membrane surface (Yeaman and Yount 2003). 
Phospholipid dislocation, decline in membrane barrier properties and/or alterations in 
membrane fluidity may consequently leads to membrane disruption.   
Peptides can develop membrane pores in microbe cells as explained earlier, this results in 
the discharge of metabolites and ions, biopolymer synthesis and loss of membrane coupled 
respiration, subsequent depolarization, and eventually cell death. However, evidence also 
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supports complementary mechanisms including inhibition of intracellular processes and 
inhibition of extracellular biopolymer synthesis as mechanisms involved in cell death 
(Yeaman and Yount 2003). 
 
History of ATP Synthase Research 
A brief history of ATP synthase written by Boris A. Feniouk (2010) and published on  
http://www.atpsynthase.info/History.html  is summarized in the following. Karl Lohmann, a 
biochemist at Kaiser Wilhelm Institute for Experimental Medicine in Heidelberg, Germany 
discovered ATP from muscle and liver extract in 1929. A Russian biochemist Vladimir 
Engelhardt in 1935 noted that ATP was part of a coenzyme complex associated with respiration 
and is required for muscle contraction. ATP had been thought-out to be the final product of 
catabolic reactions. In 1937, Herman Kalckar entrenched that ATP synthase is connected to cell 
respiration. The caption oxidative phosphorylation was coined in 1939 by Belitser and 
Tsibakova. From 1939 to 1941, Fritz Lipmann demonstrated that ATP is the principal carrier of 
chemical energy in the cell. He also invented the catchphrase "energy rich phosphate 
bonds".  Slater developed a hypothesis involving chemical intermediates to clarify the 
mechanism of oxidative phosphorylation in 1953. Coupled oxidative phosphorylation was 
reported to be triggered by the soluble factor in the bacterial particulates in 1956. In 1960, 
Penefsky and his group reported that soluble adenosine triphosphatase (ATPase) participated in 
oxidative phosphorylation, it was isolated and termed factor 1 or F1 by Ephraim Racker in 1961. 
In 1961, Robert J.P. Williams proposed that there are no energy rich intermediates however 
protons help to transfer energy to ATP synthase from the photosynthetic proteins and respiration 
chain enzymes. Also in 1961, Peter Mitchell reported his chemiosmotic hypothesis, affirming the 
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basic function of membranes that divide the two sections, and suggesting that the membrane 
proteins provide a gradient of protons created by the respiration chain enzymes, which are then 
used by ATP synthase but not by the chemical intermediates. In 1964, Paul D. Boyer suggested 
that ATP molecule is synthesized owing to structural adjustments in the ATP synthase enzyme 
and in 1973 Boyer’s group proposed that during ATP synthesis the phase which needs energy, is 
the releasing of ATP from the enzyme. Boyer and his group conceptualized the binding change 
mechanism that describes changes in the catalytic subunit of the F1FO during ATP synthesis and 
hydrolysis. The DNA sequence of genes encoding the proteins in ATP synthase was concluded 
by John E. Walker's lab. The initial X-ray crystallography configuration of the F1 subunit 
(without epsilon, delta, and part of the gamma subunits) analyzing individual amino acid 
residues was completed by Walker and his group in 1994. In 1997, Kinosita and his group 
reported direct observance of the rotation of F1 during hydrolysis of ATP. The Nobel Prize in 
chemistry in 1997 was awarded to Paul D. Boyer and John E. Walker for their illustration of the 
enzymatic mechanism fundamental to the synthesis of ATP and also to Jens C. Skou for first 
discovering ion transporting enzymes, Na+, K+ ATPase. In 2004, the initial demonstration of an 
endergonic chemical reaction being propelled by the direct precise input of mechanical energy 
was accomplished by H. Itoh and his group. 
 
Structure and Function of ATP Synthase 
ATP synthase is an F-Type ATPase. ATPases are membrane-bound enzymes capable of 
coupling ion movement through a membrane with the hydrolysis or synthesis of ATP.   Based on 
structural and functional differences, ATPases can be grouped into F-, V-, E-, P- and A-
ATPases. All these ATPases catalyze ATP synthesis or hydrolysis. The F-ATPases for 
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‘phosphorylation Factor’ are also referred to as H+-transporting ATPases or F1FO-ATPases. F-
ATPases provide a kind of transporter for H+ ions to move through the membrane and possess a 
unique rotary motor-like mechanism that is coupled with the flow of ions. ATP synthase from 
diverse taxa have amino acid sequence similarity and appear to be remarkably conserved 
throughout evolution.   F1FO-ATP synthase is also structurally and functionally similar among 
different organisms. The simplest form, and the most used model, is the Escherichia coli ATP 
synthase. The enzyme has a total molecular mass of approximately 530 kDa. E. coli ATP 
synthases have two functional rotary sectors: the intramembrane hydrophobic region called 
FO sector, and the catalytic hydrophilic F1 sector (Figure 2) (Boyer 1997). 
The FO sector consist of three subunits a, b and c, in the stoichiometry of ab2c10-14 with 
masses of about 30, 17 and 8 kDa respectively. The F1 sector has five subunits, α, β, γ, δ, and ε, 
in the stoichiometry of α3β3γδε with masses of about 55, 50, 31, 19 and 14 kDa respectively 
(Boyer 1997; Ackerman and Tzagoloff 2005). ATP synthesis and hydrolysis occur in the F1 
region, whereas proton pumping occurs through the intramembrane hydrophobic FO region 
(Senior et al. 2002, Abrahams et al. 1994). There are six possible substrate binding sites on the 
F1 sector. The binding sites on the three β-subunits are active catalytic sites, but those on the 
three α-subunits are noncatalytic regulatory sites. ATP synthase has two rotational motors, one in 
the F1 (γ and ε subunits) driven by ATP hydrolysis, the other in FO (c subunit) driven by the 
H+ gradient, which are joined together so that the two motors undergo rapid continuous 360º 
rotation as catalysis proceeds (Noji et al. 1997). The two motors are physically connected by two 
stalks. The γ subunit consists of three α-helices, two of which form a coiled coil configuration 
that insert into the central stalk of the α3β3 hexagon. The δ and b subunits form the peripheral 
stalk.  Proton gradient driven clockwise rotation of γ leads to ATP hydrolysis, and anticlockwise 
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rotation of γ results in ATP synthesis. Under mild dissociation conditions the F1FO-ATP synthase 
dissociates into the F1 and FO sectors which can be isolated and studied individually. In 
summary, the rotor consists of γεcn, while the stator consists of α3β3δab2, and the function of the 
stator is to prevent co-rotation of catalytic sites with the rotor (Itoh et al. 2004; Weber 2006). 
ATP synthase structure and function detailed studies can be found in (Noji and Yoshida 2001; 
Weber and Senior 2003; Ahmad and Senior 2005; Pedersen 2007; Senior 2007). 
 
         
 
Figure 2. Structure of F1FO ATP synthase. F1 sector contains five types of subunit with a 
stoichiometry α3β3γδε and FO contains three types of transmembrane subunits with a 
stoichiometry a1b2c10–14. (Reproduced with permission from Yoshida et al. 2001). 
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Figure 3. Cartoon representation of the structure of the isolated E. coli γε complex with 
the ε-subunit in the partially extended confirmation. A pair of α and β subunits are displayed in 
light-grey, subunit γ is dark-grey, subunit ε is displayed in the van der Waals representation (red 
is the discreet region of the β sandwich, blue is the region preserved only between bacterial and 
chloroplasts enzyme and the rest is white), βDELSEED-loop is displayed in yellow. (Reproduced 
with permission from Feniouk et al. 2006). 
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CHAPTER 2 
MATERIALS AND METHODS 
Source of Peptides and Other Chemicals 
Mastoparan B and lasioglossin II were custom synthesized by Biomatik Corporation. 
Both peptides were received as lyophilized powder shipped on dry ice and their HPLC 
determined purity was greater than 97%. Once received, they were stored at -20ºC and 
subsequently resuspended in autoclaved deionized water when needed. Other chemicals used in 
this study were ordered from Fisher Scientific, Sigma-Aldrich, and Acros organics. 
 
Preparation of E. coli Membrane Associate F1FO ATP Synthase 
Membrane bound F1FO was isolated from the E. coli strain pBWU13.4/DK8 (Ketchum et 
al. 1998). E. coli membrane bound F1FO was prepared as follows (Senior et al. 1983). Minimal 
medium was inoculated with a loop full of E. coli strain pBWU 13.4/DK8 and was aerobically 
cultivated over night at 37°C at 250 rpm. The overnight starter culture was inoculated into 1 liter 
minimal medium and grown at 37°C at 250 rpm. Growth yield was measured at OD595 (optical 
density) every hour until late log phase was reached. Once the required growth was observed the 
cells were harvested. Cells were maintained as close to 0°C as possible for subsequent steps. 
Cells were harvested by spinning the culture at 4°C in a Sorvall RC-5B refrigerated super speed 
centrifuge at 9500 rpm for 15 min. The cells were then resuspended in STEM buffer containing 
20mM sucrose and centrifuged at 9500 rpm for 25 min. The supernatant was discarded and the 
cell pellet was resuspended in 2 ml STEM/g wet cells and stored at -80°C overnight. 
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The frozen cells were thawed and mixed with DNAse to digest nucleic acids. Cells were then 
disrupted by two passages through a chilled French press cell fractionator at 20,000 psi. Cell 
debris were pelleted by centrifugation at 18K rpm for 20 min using Sorvall WX ultra-80, ultra-
centrifuge. Membrane bound ATP synthase was subsequently pelleted by spinning the 
supernatant at 60K rpm for 120 min.  
E. coli membranes were purified following a procedure consisting of three washes of the 
initial membrane pellets (Senior et al. 1984). The initial wash was performed in a buffer 
containing 50mM TES pH 7.0, 15% glycerol, 40mM 6-aminohexanoic acid, and 5mM p-
aminobenzamidine. Two subsequent washes were performed in a buffer containing 5mM TES 
pH 7.0, 15% glycerol, 40mM 6-aminohexanoic acid, 5mM p-aminobenzamidine, 0.5mM DTT 
and 0.5mM EDTA. The final membrane bound F1FO ATP synthase was resuspended and stored 
in 50 mM TrisSO4 pH 8.0, 2.5 mM MgSO4 at -80°C (Noji and Yoshida 2001). 
  
Measurement of Membrane Associated F1FO ATP Synthase Activity 
ATPase activity was measured in a 1ml assay buffer containing 10mM NaATP, 4mM 
MgCl2, and 50mM TrisSO4, at pH 8.5 and 37ºC. Reactions were initiated by the addition of 1ml 
of assay buffer to 20 µg of membrane associated F1FO ATP synthase and then terminated by 
adding SDS to 3.3% ﬁnal concentration. Inorganic phosphate (Pi) release was assayed by adding 
1ml of Taussky and Shorr (T&S) reagent containing 10 mM (NH4)6Mo7O24·4H2O, 250 mM 
Fe(NH4)2(SO4)2·6H2O, and 1.176N H2SO4. T&S reacts with Pi to form a blue color complex. 
The intensity of the blue color was measured at OD700 using Shimadzu UV-visible recording 
spectrophotometer (Taussky and Shorr 1953). Here, ATPase activity was measured in terms of 
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ATP hydrolysis rather than the synthase activity. ATPase hydrolytic activity was measured to 
test ATP synthase functionality. The hydrolysis rate is correlated to the enzyme activity, and also 
provides useful information on possible inhibitory effects of compounds that hinder the 
hydrolytic process. 
The reaction is as follows: 
ATP + ATP synthase ⇌ ADP + Pi 
Pi + T&S → blue color measured at OD700 
 
ATPase activity in µmol/min/mg was calculated using the formula: 
̳    Average Sample OD - Average Blank OD 
Amount of protein (mg) x Time (min) 
 
Inhibition of ATPase activity by Mastoparan B and Lasioglossin II 
Membrane bound F1FO ATP synthase was preincubated with varied concentrations of 
mastoparan B and lasioglossin II for 60 min at room temperature in 50 mM TrisSO4 pH 8.0. 
Then 1 ml ATPase assay buffer containing 10 mM NaATP, 4 mM MgCl2, 50 mM TrisSO4, and 
pH 8.5 was added and kept at 37ºC for 15 min to measure enzyme activity. The reaction was 
terminated by the addition of SDS to a final concentration of 3.3%. Pi release was assayed by 
adding 1ml of T&S reagent. The intensity of the blue color was assayed spectrophotometrically 
at OD700 using Shimadzu UV-visible recording spectrophotometer (Taussky and Shorr 1953). 
Data analysis was performed using Minitab software (Minitab 2014).  
% relative activity was calculated using the formula; 
   Specific activity of the test inhibitor       × 100 
                                           Specific activity of the blank 
 
  
 
29 
 
CHAPTER 3 
RESULTS 
Inhibitory Effect of Lasioglossin II on Membrane Bound E. coli ATP Synthase  
Inhibition of membrane bound E. coli ATP synthase was tested by measuring the mean 
relative ATPase activity (Figure 4) of membrane bound F1FO that had been preincubated with 
varied concentrations of lasioglossin II (10µM - 400µM) for 60 min at room temperature. The 
estimated mean was obtained from three independent inhibition experiments (Appendix D). The 
results show lasioglossin II as a very weak inhibitor (Figure 4). The maximum estimated amount 
of inhibition by lasioglossin II was ~ 18% with ~ 82% residual activity at a concentration of 
400µM. The least amount of inhibition was at a concentration of 10µM, with ~ 2% inhibition and 
~ 98% residual activity. A one-way ANOVA indicates statistically significant differences among 
the various concentrations of lasioglossin II tested (P<0.000) (Table 1). Multiple comparisons by 
Fisher’s least significant difference method indicates significant differences in the extent of 
inhibition between higher and lower concentrations of peptide (Table 2). 
 
Table 1. One – way ANOVA table for ATPase activity of membrane bound E. coli ATP synthase 
in the presence of varied concentrations of lasioglossin II 
Analysis of Variance 
Source Degrees of 
Freedom   
Adjusted Sums 
of Squares   
Adjusted 
Mean Squares   
F-Value   P-Value 
Factor 5   492.35   98.471     96.55     0.000 
Error 12       12.24    1.020 
Total 17   504.59 
Standard Deviation 1.00990   
R-square % 97.57    
Adjusted R-square % 96.56     
Predicted R-square % 94.54 
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Figure 4. Inhibition of ATPase activity of membrane bound E. coli ATP synthase in the presence 
of varied concentrations of lasioglossin II 
 
Table 2. Inhibition of ATPase activity of Escherichia coli ATP synthase enzyme and residual 
ATPase activity in the presence of lasioglossin II 
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Interval Plot of varied concentration of Lasioglossin II (µM)
Lasioglossin II 
Concentration (µM) 
% Mean Relative 
ATPase Activity 
Standard 
Deviation 
95% Confidence 
Interval 
Fisher Pairwise 
Comparisons 
10 98.10 0.59  96.63   -   99.56 A 
20 97.89 0.95 95.52   -   100.25 A 
40 96.45 0.97 94.04    -   98.86 A 
80 93.12 1.33 89.80    -  96.43 B 
100 93.06 1.44 89.47    -  96.65 B 
400 82.79 0.23 82.22    -  83.36 C 
Means that do not share a letter are significantly different. 
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Inhibitory Effect of Mastoparan B on Membrane Bound E. coli ATP Synthase 
Concentrations of mastoparan B ranged from 50 to 1000µM, with the estimated degree of 
inhibition varying from 0 to 55% (Figure 5). Membrane bound F1FO (6.1µl) was preincubated 
with varied concentrations of mastoparan B (50µM - 1000µM) for 60 min at room temperature, 
then        1 ml of ATPase assay buffer was added to measure enzyme activity. The estimated 
mean was obtained from three independent inhibition experiments (Appendix D). The maximum 
amount of inhibition estimated in the presence of mastoparan B was ~ 55%, with ~ 45 % residual 
activity at a concentration of 800µM (Figure 5). The least amount of inhibition estimated in the 
presence of mastoparan B tested was at a concentration of 50µM and was ~ 10% with ~ 90% 
residual activity (Figure 5).  Estimates of the concentration dependent inhibition are suggestive 
of a partial inhibitory effect but only at very high concentrations. A one-way ANOVA indicates 
statistically significant (P < 0.003), differences among the various peptide concentrations used 
(Table 3). Multiple comparisons by Fisher’s least significant difference method indicate 
significantly greater inhibition by 250µM, and higher concentrations of peptide and significantly 
lower inhibition at 50µM (Table 2). 
 
Table 3. One – way ANOVA table for ATPase activity of membrane bound E. coli ATP synthase 
in the presence of varied concentrations of mastoparan B 
Source Degrees of 
Freedom   
Adjusted Sums 
of Squares   
Adjusted 
Mean Squares   
F-Value   P-Value 
Factor 8      6721 840.1      4.67    0.003 
Error 18    3236    179.8 
Total 26 9957 
Standard Deviation 13.4091 
R-square % 67.50     
Adjusted R-square % 53.05     
Predicted R-square % 26.87 
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Figure 5. Inhibition of ATPase activity of membrane bound E. coli ATP synthase in the presence 
of varied concentrations of mastoparan B. 
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Table 4. Inhibition of ATPase activity of Escherichia coli ATP synthase enzyme and residual 
ATPase activity in the presence mastoparan B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mastoparan B 
Concentration (µM) 
Mean % Relative 
ATPase Activity 
Standard 
Deviation 
95% Confidence 
Interval 
Fisher Pairwise 
Comparisons 
50 90.60 23.30   32.79   -   148.41 A 
100 75.17 15.33  37.09    -   113.24 A            B          
150 76.73 14.51  40.68   -    112.78 A            B 
200 75.10 13.16 42.42   -    107.78 A            B          
250 51.13 7.42 32.70   -    69.57                             C 
300 48.30 4.95 36.00   -    60.60                             C 
400 54.03 12.29 23.51   -    84.56                B          C 
800 44.97 7.28 26.87   -    63.06                             C 
1000 47.70 13.21 14.88   -   80.52                             C 
Means that do not share a letter are significantly different. 
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CHAPTER 4 
DISCUSSION 
 
In this study the inhibitory effect on Escherichia coli ATPase activity by the two venom 
peptides lasioglossin II and mastoparan B was examined. The estimation of mean inhibitory 
effects using ANOVA reveals that varied concentrations of both lasioglossin II and mastoparan 
B were statistically significant. Varied lasioglossin II concentrations from 10µM to 100µM 
caused very low inhibition of ATPase activity (Figure 4).  At a concentration of 10µM, ~ 2% 
inhibition was observed, and only ~ 7% inhibition was seen at the concentration of 100µM. The 
maximal inhibition induced by lasioglossin II was ∼18% at a concentration of 400µM. The 
mastoparan B inhibition profile was suggestive of an interesting biological effect with maximal 
inhibition of ∼55% at a concentration of 800µM. Partial inhibition of ATP synthase by other 
potential inhibitors has been reported previously. Dadi et al. (2009) reported that the maximal 
inhibition by luteolin was ~20%, daidzein was ~10%, and galangin showed no inhibition of 
Escherichia coli ATPase activity. Previous studies have also shown that a variety of linear 
cationic α-helical AMPs inhibit ATP synthase to varying degrees. Laughlin and Ahmad 2010 
reported that amphibian AMPs aurein 2.2, aurein 2.3, carein 1.9, magainin II, and magainin II-
amide gave partial inhibitory effects of ∼69%, 30%, 52%, 20% and 60% respectively at very low 
molar concentrations, while carein 1.8 did not inhibit at all (0%). The honey bee venom peptides 
melittin and melittin-amide inhibited ∼77% and ∼95% of enzyme activity respectively, while 
melittin related peptide (MRP) and MRP-amide inhibited at ∼79% and ∼96% respectively.  
The results obtained from this study also contrasts with results obtained on the inhibition 
of ATP synthase by other venom peptides. Azim et al. (2016) documented the inhibitory effect 
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of four venom peptides on Escherichia coli ATP synthase also at much lower concentrations 
than the concentrations used in this study. King cobra OH-CATH (KF-34), wolf spider lycotoxin 
II (KE-27), banded krait cathelicidin (BF-30), and wolf spider lycotoxin I (IL-25) induced very 
strong inhibition of ATP synthase, as the maximum inhibition caused by KF-34, KE-27, BF-30 
and IL-25 was ∼90%, ∼85%, ∼85% and ∼88% respectively. 
The partial or slight inhibition obtained in this study might be the result of various 
factors, inclusive of the sequence length of the peptides, cationicity, and amphipathic character. 
The sequence length of the venom peptides OH-CATH (KF-34), cathelicidin (BF-30), lycotoxin 
II (KE-27) and lycotoxin I (IL-25) are 34, 30, 27 and 25 amino-acids respectively, while 
lasioglossin II and mastoparan B have lengths of 15 and 14 amino acids. In antibacterial studies 
of two derivatives of esculentin-1 peptides, Esc-1a (1-21) NH2 was two to eight fold more active 
against the planktonic form and exhibited a stronger anti-biofilm activity, inducing a 3 log 
decrease in the amount of viable biofilm cells than Esc-1b (1-18) NH2 in many distinct strains of 
the bacteria Pseudomonas aeruginosa. This difference was attributed to the longer length and 
higher cationicity of Esc-1a (1-21) NH2 (Mangoni et al. 2015). Two additional factors play vital 
responsibility in the action mechanism of AMPs, a net positive charge at neutral pH, because 
cationicity depicts essential character that supports the interaction and binding of AMPs to the 
negatively charged constituents of the microbial cell membrane, and amphipathic character 
because this parameter affects the integration of specific peptide into the hydrophobic core of the 
membrane lipid bilayers (Rietschel et al. 1994; Teixeira et al. 2012). The net positive charge and 
the hydrophobic face of OH-CATH (KF-34), cathelicidin (BF-30), lycotoxin I (IL-25) and 
lycotoxin II (KE-27) are also greater than that of lasioglossin II and mastoparan B.  
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Cytolytic peptides with high antimicrobial activity such as lasioglossins and mastoparans 
obtained from the venom of stinging insects have some characteristics that suggested them as 
candidates for the development of effective antibiotic peptides based on their potential for anti-
ATP synthase activity.  In this study, statistically significant differences in ATP synthase activity 
were observed in experiments with lasioglossin II, but the effects appear to have very limited 
biological relevance. The results of inhibition experiments with mastoparan B were statistically 
significant and were suggestive of some biologically relevant effects on ATP synthase.  
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APPENDICES 
APPENDIX A- Abbreviations 
AMP- Antimicrobial Peptide 
ATP- Adenosine triphosphate  
ADP- Adenosine diphosphate  
Leu [L] - Leucine  
Lys [K] - Lysine  
Ser [S] - Serine  
Ile [I] - Isoleucine 
Val [V] - Valine  
Arg [R] - Arginine  
Trp [W] - Tryptophan 
Ala [A] - Alanine  
Asn [N] - Asparagine  
Gly [G] - Glycine  
NBD-Cl- 4-chloro-7-nitrobenzofurazan  
PAB- 4-aminobenzamidine  
Pi - Inorganic phosphate 
SDS- Sodium dodecyl sulphate  
T&S- Taussky and Shorr  
O.D- Optical density  
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APPENDIX B: Buffers and Reagents 
50 mM Tris-SO4 buffer 
To 90 ml H2O add 
0.61 g Tris 
Adjust pH to 8.0 with H2SO4 
Bring to a final volume of 100 ml with H2O 
 
ATPase cocktail 
In 150 ml H2O add 
10 ml 1 M Tris 
0.8 ml 1M MgCl2 
5 ml 0.4 Na ATP (Adenosine 5̍-triphosphate disodium salt) 
Adjust pH to 8.5 with H2SO4 
Bring to a final volume of 200 ml with H2O 
Freeze in plastic bottles at -20oC 
10 % SDS 
100 gm Sodium dodecyl sulfate 
Bring to a final volume of 1000 ml with H2O 
Taussky and Shorr reagent (T & S reagent) 
Sol A: 1.2 g Ammonium molybdate ((NH4)6Mo7O24·4H2O in 9.8 ml 12 N H2SO4) 
Sol B: 10 g Ferrous ammonium sulfate (Fe(NH4)2(SO4)2·6H2O in 70 ml H2O) 
Add sol A to sol B while stirring 
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Bring to a final volume of 100 ml with H2O 
Store at 4oC 
STEM 
To 700 ml H2O add 
100 ml 1 M TES 
4.29 g Mg(CH3CO2)2·4H2O 
85.5 g sucrose 
0.0951 g EGTA (Ethylene glycol-bis(2-aminoethylether)-N,N,N,N-tetraacetic acid) 
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid) 
Adjust pH to 6.5 with NaOH 
Bring to a final volume of 1000 ml with H2O 
Freeze in plastic bottles at -20oC 
TES 50 
To 700 ml H2O add 
50 ml 1 M TES 
150 ml glycerol 
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid) 
1 g PAB (4-Aminobenzamidine dihydrochloride) 
Adjust pH to6.5 with NaOH 
Bring to a final volume of 1000 ml with H2O 
Freeze in plastic bottles at -20oC 
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TES 5 + PAB 
To 700 ml H2O add 
5 ml 1 M TES 
150 ml glycerol 
1 ml 0.5 M DTT (Dithiothreitol) 
5 g EACA (6-Ainocaproic acid6-Ainocaproic acid) 
1 g PAB (4-Aminobenzamidine dihydrochloride) 
2.5 ml 0.2 M EDTA (Ethylenediaminetetraacetic acid disodium salt dihydrate)  
Adjust pH to 6.5 with NaOH 
Freeze in plastic bottles at -20oC 
 
AET (Argenine Ent Thimine) 
To 60 ml H2O add 
0.617 g 2,3 Dihydroxy Benzoic acid 
16.86 g L-Arginine HcL 
1 ml 20 mM Thiamine 
Add just enough amount of NaOH to dissolve everything 
Make final volume to 100 ml with H2O 
Filter sterile 
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TE (Trace Elements) 
To 80 ml H2O 
0.251 g Zinc Sulfate (ZnSO4.7H2O) 
0.017 g Manganese Sulfate (MnSO4.H2O) 
0.029 g Boric acid (H3BO3) 
0.012 g Calcium Sulfate (CaSO4.2H2O) 
0.037 g Calcium Chloride (CaCl2.2H2O)  
0.049 g Ferric Chloride (FeCl3.6H2O) 
Make final volume to 100 ml with H2O 
Filter sterile 
 
ILV (Isoleucin-Valine) 
To 95 ml H2O add 
0.394 g Isoleucine 
0.352 g Valine 
Make final volume to 100 ml with H2O 
Filter sterile 
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APPENDIX C: Culture Media and Plates 
LB liquid medium 
 
12.5 g of LB broth powder 
Add H2O to bring to 500 ml 
Autoclave for 30 minutes 
Cool the media to ~50oC 
Add 500 µl of 100 mg/ml Ampicillin 
Minimal Glucose 
 
To 400 ml H2O add 
5.225 g Potassium Phosphate Dibasic Trihydrate (K2HPO4) 
2.40 g Sodium Phosphate Monobasic (NaH2PO4) 
0.99 g Ammonium Sulfate ((NH4)2SO4) 
Autoclave for 30 min, cool it and add the following additions 
10 ml Uracil 
10 ml 27 % Glucose 
5 ml ILV (isoleucin-valine) 
0.5 ml TE (trace elements)  
0.5 ml 1 M Magnesium Sulfate (MgSO4) 
0.5 ml AET (Argenine Ent Thimine) 
0.5 ml 100 mg/ml Ampicillin 
0.312 ml 4X LB 
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LB-Agar plate with Ampicillin 
12.5g of LB broth powder 
7.5g of agar 
Bring to a final volume of 500 mL 
Autoclave for 30 minutes 
Cool the media to ~50oC 
Add 500 µl of 100 mg/ml Ampicillin 
Pour into sterile plates 
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APPENDIX D: Raw data 
Result of three independent experiment 
 
Lasioglossin II 
Conc. (µM) 
A B C % Mean Relative 
ATPase Activity 
Standard 
Deviation 
10 98.36 98.51 97.42 98.10 0.59 
20 96.79 98.51 98.36 97.89 0.95 
40 97.57 95.93 95.85 96.45 0.97 
80 93.51 94.21 91.63 93.12 1.33 
100 93.43 91.47 94.29 93.06 1.44 
400 82.79 82.56 83.02 82.79 0.23 
 
 
Mastoparan B 
Conc. (µM) 
A B C % Mean Relative 
ATPase Activity 
Standard 
Deviation 
50 107.7 64.1 100 90.60 23.27 
100 69.6 92.5 63.4 75.17 15.33 
150 61.9 77.4 90.9 76.73 14.51 
200 60 81.2 84.1 75.10 13.16 
250 49.6 44.6 59.2 51.13 7.42 
300 52.4 49.7 42.8 48.30 4.95 
400 67.7 43.9 50.5 54.03 12.29 
800 52.8 38.4 43.7 44.97 7.28 
1000 34.8 61.2 47.1 47.70 13.21 
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